Home › Trials › NCT06588283

Combining ixekizumab and tirzepatide for treating psoriasis and obesity

Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)

Phase 3 Interventional Eli Lilly and Company · NCT06588283

This study is testing if using ixekizumab with tirzepatide can help adults with moderate to severe psoriasis who are also overweight or obese feel better and lose weight more effectively than just using ixekizumab alone.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment250 (estimated)
Ages18 Years and up
SexAll
SponsorEli Lilly and Company Industry-sponsored
Drugs / interventionsixekizumab
Locations72 sites (Birmingham, Alabama and 71 other locations)
Trial IDNCT06588283 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the effectiveness of administering ixekizumab alongside tirzepatide in adults suffering from moderate to severe plaque psoriasis and obesity or overweight. Participants will undergo up to 12 visits over a period of 61 weeks, which includes screening, treatment, and follow-up phases. The primary goal is to assess improvements in psoriasis symptoms and weight reduction compared to treatment with ixekizumab alone. The study focuses on individuals with specific weight-related comorbid conditions to determine the combined treatment's efficacy.

Who should consider this trial

Good fit: Ideal candidates are adults with moderate-to-severe plaque psoriasis and obesity or overweight, specifically those with at least one weight-related comorbidity.

Not a fit: Patients with Type 1 Diabetes Mellitus, insulin-treated Type 2 Diabetes Mellitus, or those with certain medical histories may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to improved psoriasis management and weight loss for patients with these concurrent conditions.

How similar studies have performed: While the combination of these specific treatments is novel, previous studies have shown success with similar approaches in managing psoriasis and obesity.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Have a diagnosis of moderate-to-severe plaque psoriasis (PsO) for at least 6 months.
* Have both a Static Physician's Global Assessment (sPGA) score of ≥3 and a Psoriasis Area and Severity Index (PASI) ≥12.
* Have ≥10% body surface area (BSA) involvement.
* Have obesity, body mass index of ≥30 kilograms per meter squared (BMI ≥30 kg/m²) or overweight (BMI ≥27 to \<30 kg/m²) in the presence of at least 1 of these weight-related comorbid conditions (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2DM).

Exclusion Criteria:

Medical Conditions

* Have Type 1 Diabetes Mellitus (T1DM).
* Have insulin-treated Type 2 Diabetes Mellitus (T2DM).
* Have a prior or planned surgical treatment for obesity.
* Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.
* Have active, or a history of inflammatory bowel disease (Crohn's or ulcerative colitis).
* Have a diagnosis or history of malignant disease within the 5 years prior to randomization, with the following exceptions:

  * basal cell or squamous epithelial carcinomas of the skin that have been resected, with no evidence of metastatic disease for 3 years.
  * cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to randomization.
* Have serious disorder or illness other than PsO.
* Have a history of chronic or acute pancreatitis.
* Have any prior use of ixekizumab or tirzepatide.
* Have a previous failure or intolerance to an interleukin 17 inhibitor (IL-17i) or glucagon-like peptide 1 (GLP-1) receptor agonists.

Where this trial is running

Birmingham, Alabama and 71 other locations

+22 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions PsoriasisObesity
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.